- $234.33bn
- $260.91bn
- $45.81bn
- 89
- 22
- 60
- 57
REG - AstraZeneca PLC - YTD and Q3 2022 Results
AnnouncementREG - AstraZeneca PLC - FDA Advisory Committee recommends PT027 in asthma
AnnouncementREG - AstraZeneca PLC - Beyfortus (nirsevimab) approved in EU
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Capivasertib Phase III trial met primary endpoints
AnnouncementREG - AstraZeneca PLC - Update on MESSINA Phase III trial
AnnouncementREG - AstraZeneca PLC - Imfinzi + Imjudo approved in advanced liver cancer
AnnouncementREG - Polar Cap Glb Health PCGH ZDP PLC - Top Ten Equity Holdings and Exposures
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Board Committee Changes
AnnouncementREG - AstraZeneca PLC - Koselugo approved in Japan for NF1
AnnouncementREG - AstraZeneca PLC - Tezspire approved in Japan for severe asthma
AnnouncementREG - AstraZeneca PLC - Ultomiris approved in EU for gMG
AnnouncementREG - AstraZeneca PLC - Lynparza approved in China for ovarian cancer
AnnouncementREG - AstraZeneca PLC - Tezspire approved in the EU for severe asthma
AnnouncementREG - AstraZeneca PLC - Evusheld approved in EU for COVID-19 treatment
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Evusheld positive CHMP opinion in EU
AnnouncementREG - AstraZeneca PLC - Danicopan Phase III trial met primary endpoint
Announcement